Sin and Laura Zam describe persistent post-treatment difficulties

An NPR report by Will Stone, published Nov. 19, says psychedelics could transform mental health care and are being heralded for their potential to treat devastating mental illnesses. Host Sacha Pfeiffer introduced the segment by noting that some worry there is not enough attention to how people fare in the aftermath. Advocates and researchers say the minority of people with persistent troubles after using these drugs has received too little attention, and Pedram Dara worries some may end up destabilized, with persistent problems and maybe worse off months later.

Clinical trials do track adverse events. Roman Palitsky, a research psychologist at Emory University School of Medicine, said stories of this kind reach him many times a week and that the evidence contains large blind spots. The accounts NPR described include Sin, whose depression began to lift after a 5-MeO-DMT trial for treatment-resistant depression, and Laura Zam, whose husband Kurt was institutionalized five times in six months for suicidal ideation after an MDMA trial for cancer survivors and their caregivers.

Trials track adverse events but follow-up falls short

Serious adverse events tracked in clinical trials include suicidality, prolonged psychotic episodes and medical emergencies that require hospitalization. One major review described by NPR suggested that such events are very rare in clinical trials but also underreported. Palitsky agreed that the evidence has large blind spots. People, he said, are not followed long enough, and the full array of troubles is not captured — “everything from existential distress to anxiety to feeling disassociated.”

Palitsky said he hears accounts like these many times a week: “These are very effective therapies, and they can help a lot of people. Talking about adverse effects is not contra to their effectiveness, and we just need to be candid about it.” He also said: “Psychedelics just have this broad-spectrum, robust effect on so many domains of people’s experience. And so our assessment of adverse effects have to keep up.” His team at Emory is running a study tracking people with these problems for a year to build a more detailed picture.

Jules Evans, who directs the Challenging Psychedelic Experiences Project, a nonprofit that researches these issues, said: “Many people, even who offer psychedelic treatments, legal psychedelic treatments, have no idea that people can get into these difficulties for weeks or months or years afterwards. And so when it occurs, they’re bewildered.”

Sin’s depression began to lift before anxiety and panic followed

Sin, a pseudonym, asked NPR not to use her full name because she was concerned that sharing her experience could affect her employment. She had enrolled in a clinical trial testing the fast-acting psychedelic 5-MeO-DMT for treatment-resistant depression. In theory, she knew what to expect before taking a nasal spray of the drug, but she said: “Honestly, whatever you tell people before they actually experience it, it’s not going to make any sense. You’ll feel like you’ll be tied to a rocket ship, for example, means nothing to me.”

During the session, she described a moment when everything went white and wondered whether she had died. She said: “I, at some point, had, like, nothing. So it was all white. OK, have I died? Is this what death is like?” When she came back to reality, she left the clinic and was soon riding the underground in London during rush hour. The session was jarring, and in the months that followed, readjusting to life was hard. She said: “Like a very thin skin almost to your emotions.”

Her persistent depression began to lift, but in its place came intense anxiety and panic attacks. At one point she asked her therapist: “Did I do something wrong in choosing to do this trial?” Sin also said that at one point she worried she might have broken her brain. Her situation did slowly get better, though the recovery was monthslong and sometimes agonizing. She is grateful for how the psychedelic treatment helped her depression, but she was unprepared for that recovery process.

She said she hopes the risks do not get lost in the rush to make these drugs more available. Sin said: “When you read the news, obviously, it’s all about, oh, it treats depression. Great. But then what does it leave you with? It’s just the unpredictability of it, I think, is not necessarily appreciated.”

Kurt’s hospitalizations left his family seeking answers

Laura Zam has asked a similar question for years about her husband, Kurt. When he was in remission from pancreatic cancer, the couple enrolled in an MDMA trial for cancer survivors and their caregivers. Zam said he was initially elated with the experience, but she soon became concerned. She said: “His brain, I noticed, just worked a little bit differently. He stopped sleeping, couldn’t turn off this rumination and worry.”

The situation spiraled, Zam said: “To such a degree that he was institutionalized five times over the course of the next six months. He kept having to go back to the hospital because of this suicidal ideation.” Those involved in his care did not seem to know enough about psychedelics, she said, to say whether that could have been responsible or what to do about it. It took years to find him the right help. “He’s still pretty sick, but he is coming back little by little,” she said.

Patient groups and the research response

Dara went through his own difficulties after MDMA-assisted therapy in a trial in Canada. He said: “Like, a safe session or safe dosing session doesn’t mean safe outcome.” Dara said the aftermath can be mixed and warned against reading the field in binary terms: “It’s not so binary, like, oh, this was a miracle cure or treatment or completely harmed the individual.”

The patient-led Psychedelic Lived Experiences initiative, which Dara started, is holding a summit exploring what happens to people after taking these drugs and also runs a peer support group. Dara said: “Whether it worked for you or didn’t, there was this need to connect with others who had gone through it just so that you could feel understood.”

NPR reported that evidence-based treatments are unavailable for many post-psychedelic challenges; Evans said therapy does seem to help. The report noted that the Food and Drug Administration could approve psychedelics like psilocybin for mental health treatment next year, and that other drugs are in the pipeline. When people are under the influence, doctors monitor them closely.